此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic Syndromes

2026年8月25日 更新者:Sichuan Baili Pharmaceutical Co., Ltd.

A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of BL-M11D1 for Injection in Patients With Relapsed/Refractory Myelodysplastic Syndromes

This study is an open-label, multicenter, non-randomized Phase Ib/II clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of BL-M11D1 for injection in patients with relapsed/refractory myelodysplastic syndromes.

研究概览

地位

尚未招聘

干预/治疗

详细说明

The study consists of two phases: a dose-exploration phase (Phase Ib) and a dose-expansion phase (Phase II).

研究类型

介入性

注册 (估计的)

92

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国
        • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
        • 接触:
          • Zhijian Xiao

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Voluntarily sign the informed consent form and comply with the protocol requirements;
  2. No gender restrictions;
  3. Age: ≥18 years and ≤75 years;
  4. Expected survival time ≥3 months;
  5. Relapsed/refractory CD33+ MDS;
  6. Morphological assessment showing blasts in bone marrow ≥5% and <20%;
  7. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
  8. Toxicities from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;
  9. Meet the required organ function levels;
  10. For premenopausal women of childbearing potential, a pregnancy test (serum/urine) must be negative within 7 days before starting treatment, and they must not be breastfeeding; all enrolled trial participants (regardless of gender) must practice adequate barrier contraception throughout the entire treatment period and for 6 months after treatment completion.

Exclusion Criteria:

  1. Use of chemotherapy, biotherapy, immunotherapy, etc., within 4 weeks or 5 half-lives prior to the first dose;
  2. Presence of uncorrected folate deficiency or vitamin B12 deficiency, etc.;
  3. History of severe cardiovascular or cerebrovascular disease;
  4. Thromboembolic events requiring therapeutic intervention within 6 months prior to screening;
  5. Active autoimmune diseases and inflammatory diseases;
  6. History of extensive bowel resection or presence of Crohn's disease, ulcerative colitis, chronic diarrhea, or intestinal obstruction;
  7. Diagnosis of another malignancy within 5 years prior to the first dose;
  8. Poorly controlled hypertension;
  9. Poorly controlled hyperglycemia or diabetes mellitus;
  10. Pulmonary diseases classified as Grade ≥3 according to CTCAE v6.0, etc.;
  11. Trial participants with central nervous system involvement;
  12. Trial participants with extramedullary involvement;
  13. Trial participants with a history of allergy to recombinant humanized antibodies or chimeric human-mouse antibodies, or hypersensitivity to any excipient component of BL-M11D1;
  14. Prior organ transplantation or hematopoietic stem cell transplantation;
  15. Positive for human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
  16. Active fungal, bacterial, or viral infections;
  17. History of severe neurological or psychiatric disorders;
  18. Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
  19. Presence of clinically symptomatic pleural, peritoneal, or pericardial effusion requiring repeated drainage;
  20. Participation in another clinical trial within 4 weeks or 5 half-lives prior to the first dose;
  21. Pregnant or breastfeeding women;
  22. Other conditions deemed by the investigator to make the participant unsuitable for participation in this clinical trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BL-M11D1
Participants receive BL-M11D1 for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
通过静脉输注给药,周期为4周。

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
第二阶段:客观缓解率 (ORR)
大体时间:最长约 24 个月
ORR 定义为达到 CR(所有目标病灶消失)或 PR(目标病灶直径总和至少减少 30%)的参与者百分比。 经历确认的 CR 或 PR 的参与者的百分比根据 RECIST 1.1 计算。
最长约 24 个月
Phase Ib: Recommended Phase II Dose (RP2D)
大体时间:Up to approximately 24 months
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M11D1.
Up to approximately 24 months
Phase Ib: Treatment-Emergent Adverse Event (TEAE)
大体时间:Up to approximately 24 months
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M11D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M11D1.
Up to approximately 24 months
Phase II: Complete Response (CR)
大体时间:Up to approximately 24 months
Complete Response (CR) is defined as the disappearance of all target lesions, with any pathological lymph nodes (whether target or non-target) having a short axis diameter reduced to <10 mm.
Up to approximately 24 months

次要结果测量

结果测量
措施说明
大体时间
AUC0-t
大体时间:最长约 24 个月
AUC0-t 定义为从时间 0 到最后可测量浓度的时间的血清浓度-时间曲线下的面积。
最长约 24 个月
Cmax
大体时间:最长约24个月
将研究BL-M11D1的最大血清浓度(Cmax)。
最长约24个月
Tmax
大体时间:最长约24个月
将研究BL-M11D1达到最大血清浓度的时间(Tmax)。
最长约24个月
Ctrough
大体时间:最长约 24 个月
Ctrough被定义为在施用下一剂量之前BL-M11D1的最低血清浓度。
最长约 24 个月
ADA(抗药物抗体)
大体时间:最长约24个月
将研究抗BL-M11D1抗体(ADA)的频率。
最长约24个月
T1/2
大体时间:Up to approximately 24 months
Half-life (T1/2) of BL-M11D1 will be investigated.
Up to approximately 24 months
CL (Clearance)
大体时间:Up to approximately 24 months
CL in the serum of BL-M11D1 per unit of time will be investigated.
Up to approximately 24 months
Phase II: Duration of Response (DOR)
大体时间:Up to approximately 24 months
The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.
Up to approximately 24 months
Phase II: Hematologic Improvement (HI)
大体时间:Up to approximately 24 months
HI is defined as achieving a predefined threshold of improvement in the erythroid, platelet, or neutrophil lineages according to the IWG 2006 and IWG 2023 criteria, with a duration of no less than 8 weeks.
Up to approximately 24 months
Phase II: AML Transformation Rate
大体时间:Up to approximately 24 months
The AML transformation rate is defined as the first confirmed event of transformation to acute myeloid leukemia according to WHO criteria (bone marrow blasts ≥20% or presence of extramedullary infiltration).
Up to approximately 24 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年5月9日

首先提交符合 QC 标准的

2026年5月9日

首次发布 (实际的)

2026年5月15日

研究记录更新

最后更新发布 (实际的)

2026年8月27日

上次提交的符合 QC 标准的更新

2026年8月25日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • BL-M11D1-102

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅